Cargando…

The molecular landscape of extraskeletal osteosarcoma: A clinicopathological and molecular biomarker study

Extraskeletal osteosarcoma (ESOSA) is a rare soft tissue neoplasm representing <5% of osteosarcomas and <1% of all soft‐tissue sarcomas. Herein, we investigate the clinicopathological and molecular features of ESOSA and explore potential parameters that may affect outcome. Thirty‐two cases wer...

Descripción completa

Detalles Bibliográficos
Autores principales: Jour, George, Wang, Lu, Middha, Sumit, Zehir, Ahmet, Chen, Wen, Sadowska, Justyna, Healey, John, Agaram, Narasimhan P, Choi, Lisa, Nafa, Khedoudja, Hameed, Meera
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4858130/
https://www.ncbi.nlm.nih.gov/pubmed/27499911
http://dx.doi.org/10.1002/cjp2.29
_version_ 1782430758161350656
author Jour, George
Wang, Lu
Middha, Sumit
Zehir, Ahmet
Chen, Wen
Sadowska, Justyna
Healey, John
Agaram, Narasimhan P
Choi, Lisa
Nafa, Khedoudja
Hameed, Meera
author_facet Jour, George
Wang, Lu
Middha, Sumit
Zehir, Ahmet
Chen, Wen
Sadowska, Justyna
Healey, John
Agaram, Narasimhan P
Choi, Lisa
Nafa, Khedoudja
Hameed, Meera
author_sort Jour, George
collection PubMed
description Extraskeletal osteosarcoma (ESOSA) is a rare soft tissue neoplasm representing <5% of osteosarcomas and <1% of all soft‐tissue sarcomas. Herein, we investigate the clinicopathological and molecular features of ESOSA and explore potential parameters that may affect outcome. Thirty‐two cases were retrieved and histomorphology was reviewed. Clinical history and follow‐up were obtained through electronic record review. DNA from formalin‐fixed paraffin‐embedded (FFPE) tissue was extracted and processed from 27 cases. Genome‐wide DNA copy number (CN) alterations and allelic imbalances were analyzed by single nucleotide polymorphism array using Affymetrix OncoScan FFPE Assay. Massive high‐throughput deep parallel sequencing was performed using a customized panel targeting 410 cancer genes. Log rank, Fisher's exact test and Cox proportional hazards were used for statistical analysis. In this series of 32 patients (male n = 12, female n = 20), the average age was 66 years (19–93) and median follow up was 24 months (range 6–120 months). Frequent genomic alterations included CN losses in tumour suppressor genes including CDKN2A (70%), TP53 (56%) and RB1 (49%). Mutations affecting methylation/demethylation, chromatin remodeling and WNT/SHH pathways were identified in 40%, 27%, and 27%, respectively. PIK3CA and TERT promoter variant mutations were identified in 11% of the cases. Cases harbouring simultaneous TP53 and RB1 biallelic CN losses were associated with worse overall survival and local recurrence (p = 0.04, p = 0.02, respectively). CDKN2A losses and positive margins were also associated with worse overall survival (p = 0.002; p = 0.03, respectively). Our findings suggest that age above 60, positive margin status, simultaneous biallelic TP53 and RB1 losses and CDKN2A loss are associated with a worse outcome in ESOSA. Comparison between conventional paediatric osteosarcoma and ESOSA shows that, while both share genetic similarities, there are notable dissimilarities and mechanistic differences in the molecular pathways involved in ESOSA.
format Online
Article
Text
id pubmed-4858130
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-48581302016-08-05 The molecular landscape of extraskeletal osteosarcoma: A clinicopathological and molecular biomarker study Jour, George Wang, Lu Middha, Sumit Zehir, Ahmet Chen, Wen Sadowska, Justyna Healey, John Agaram, Narasimhan P Choi, Lisa Nafa, Khedoudja Hameed, Meera J Pathol Clin Res Original Articles Extraskeletal osteosarcoma (ESOSA) is a rare soft tissue neoplasm representing <5% of osteosarcomas and <1% of all soft‐tissue sarcomas. Herein, we investigate the clinicopathological and molecular features of ESOSA and explore potential parameters that may affect outcome. Thirty‐two cases were retrieved and histomorphology was reviewed. Clinical history and follow‐up were obtained through electronic record review. DNA from formalin‐fixed paraffin‐embedded (FFPE) tissue was extracted and processed from 27 cases. Genome‐wide DNA copy number (CN) alterations and allelic imbalances were analyzed by single nucleotide polymorphism array using Affymetrix OncoScan FFPE Assay. Massive high‐throughput deep parallel sequencing was performed using a customized panel targeting 410 cancer genes. Log rank, Fisher's exact test and Cox proportional hazards were used for statistical analysis. In this series of 32 patients (male n = 12, female n = 20), the average age was 66 years (19–93) and median follow up was 24 months (range 6–120 months). Frequent genomic alterations included CN losses in tumour suppressor genes including CDKN2A (70%), TP53 (56%) and RB1 (49%). Mutations affecting methylation/demethylation, chromatin remodeling and WNT/SHH pathways were identified in 40%, 27%, and 27%, respectively. PIK3CA and TERT promoter variant mutations were identified in 11% of the cases. Cases harbouring simultaneous TP53 and RB1 biallelic CN losses were associated with worse overall survival and local recurrence (p = 0.04, p = 0.02, respectively). CDKN2A losses and positive margins were also associated with worse overall survival (p = 0.002; p = 0.03, respectively). Our findings suggest that age above 60, positive margin status, simultaneous biallelic TP53 and RB1 losses and CDKN2A loss are associated with a worse outcome in ESOSA. Comparison between conventional paediatric osteosarcoma and ESOSA shows that, while both share genetic similarities, there are notable dissimilarities and mechanistic differences in the molecular pathways involved in ESOSA. John Wiley and Sons Inc. 2015-10-29 /pmc/articles/PMC4858130/ /pubmed/27499911 http://dx.doi.org/10.1002/cjp2.29 Text en © 2015 John Wiley and Sons Ltd and The Pathological Society of Great Britain and Ireland This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Jour, George
Wang, Lu
Middha, Sumit
Zehir, Ahmet
Chen, Wen
Sadowska, Justyna
Healey, John
Agaram, Narasimhan P
Choi, Lisa
Nafa, Khedoudja
Hameed, Meera
The molecular landscape of extraskeletal osteosarcoma: A clinicopathological and molecular biomarker study
title The molecular landscape of extraskeletal osteosarcoma: A clinicopathological and molecular biomarker study
title_full The molecular landscape of extraskeletal osteosarcoma: A clinicopathological and molecular biomarker study
title_fullStr The molecular landscape of extraskeletal osteosarcoma: A clinicopathological and molecular biomarker study
title_full_unstemmed The molecular landscape of extraskeletal osteosarcoma: A clinicopathological and molecular biomarker study
title_short The molecular landscape of extraskeletal osteosarcoma: A clinicopathological and molecular biomarker study
title_sort molecular landscape of extraskeletal osteosarcoma: a clinicopathological and molecular biomarker study
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4858130/
https://www.ncbi.nlm.nih.gov/pubmed/27499911
http://dx.doi.org/10.1002/cjp2.29
work_keys_str_mv AT jourgeorge themolecularlandscapeofextraskeletalosteosarcomaaclinicopathologicalandmolecularbiomarkerstudy
AT wanglu themolecularlandscapeofextraskeletalosteosarcomaaclinicopathologicalandmolecularbiomarkerstudy
AT middhasumit themolecularlandscapeofextraskeletalosteosarcomaaclinicopathologicalandmolecularbiomarkerstudy
AT zehirahmet themolecularlandscapeofextraskeletalosteosarcomaaclinicopathologicalandmolecularbiomarkerstudy
AT chenwen themolecularlandscapeofextraskeletalosteosarcomaaclinicopathologicalandmolecularbiomarkerstudy
AT sadowskajustyna themolecularlandscapeofextraskeletalosteosarcomaaclinicopathologicalandmolecularbiomarkerstudy
AT healeyjohn themolecularlandscapeofextraskeletalosteosarcomaaclinicopathologicalandmolecularbiomarkerstudy
AT agaramnarasimhanp themolecularlandscapeofextraskeletalosteosarcomaaclinicopathologicalandmolecularbiomarkerstudy
AT choilisa themolecularlandscapeofextraskeletalosteosarcomaaclinicopathologicalandmolecularbiomarkerstudy
AT nafakhedoudja themolecularlandscapeofextraskeletalosteosarcomaaclinicopathologicalandmolecularbiomarkerstudy
AT hameedmeera themolecularlandscapeofextraskeletalosteosarcomaaclinicopathologicalandmolecularbiomarkerstudy
AT jourgeorge molecularlandscapeofextraskeletalosteosarcomaaclinicopathologicalandmolecularbiomarkerstudy
AT wanglu molecularlandscapeofextraskeletalosteosarcomaaclinicopathologicalandmolecularbiomarkerstudy
AT middhasumit molecularlandscapeofextraskeletalosteosarcomaaclinicopathologicalandmolecularbiomarkerstudy
AT zehirahmet molecularlandscapeofextraskeletalosteosarcomaaclinicopathologicalandmolecularbiomarkerstudy
AT chenwen molecularlandscapeofextraskeletalosteosarcomaaclinicopathologicalandmolecularbiomarkerstudy
AT sadowskajustyna molecularlandscapeofextraskeletalosteosarcomaaclinicopathologicalandmolecularbiomarkerstudy
AT healeyjohn molecularlandscapeofextraskeletalosteosarcomaaclinicopathologicalandmolecularbiomarkerstudy
AT agaramnarasimhanp molecularlandscapeofextraskeletalosteosarcomaaclinicopathologicalandmolecularbiomarkerstudy
AT choilisa molecularlandscapeofextraskeletalosteosarcomaaclinicopathologicalandmolecularbiomarkerstudy
AT nafakhedoudja molecularlandscapeofextraskeletalosteosarcomaaclinicopathologicalandmolecularbiomarkerstudy
AT hameedmeera molecularlandscapeofextraskeletalosteosarcomaaclinicopathologicalandmolecularbiomarkerstudy